Trial endpoints: is it time to get selective on surrogates?
Health policy professor Dr Huseyin Naci discusses the risks of leaning too hard on surrogate endpoints in clinical research.
By
Accelerating Clinical Trials
Latest in
Accelerating Clinical Trials
Tools4Patient Q&A: predicting the placebo response to cut trial failure rates
Placebell is a tool that helps to remove the risk of the placebo phenomenon in clinical trials, reducing the risk…
By
Liquid biopsy tech: non-invasive cancer monitoring in clinical trials
Liquid biopsy company Angle recently secured its first large-scale pharma services contract. Clinical Trials Arena caught up with the firm’s…
By
SaNOtize’s “revolutionary” Covid-19 nasal spray bolstered by Phase II trial data
A self-administered nitric oxide nasal spray (NONS) made by Vancouver-based biotech firm SaNOtize has been found to dramatically reduce Covid-19…
By
Trials of Covid-19 long-hauler therapies could repurpose endpoints from other disease studies but evolving definitions pose challenges, experts say
Covid-19 long-hauler treatment trials will likely rely on established endpoints and trial design features used in other conditions, and will…
By
Partner content
How a drug development plan can save your biotech money
The drug development industry has seen a major shift of clinical activity away from large pharmaceutical companies in favour of…
The benefit of running clinical trials in Asia-Pacific for biotech companies
According to Frost & Sullivan, the CRO market is forecast to grow to US$ 71.7billion by 2024 (+8% CAGR 19-24F).…
By
Partner content
Is Australia the future for successful first-in-human clinical studies?
The number of biotech-sponsored clinical trials in Australia has grown by more than +10% on average each year between 2017…